$BBIO

BridgeBio Pharma (BBIO) shares fell due to inclusion in the Medicaid Most Favored Nation pricing system, which investors fear will lead to price cuts. The decline is exacerbated by a broader biotech selloff and concerns over a recent shareholder offering. Despite growth in its Attruby franchise, the company faces regulatory and financial challenges, including significant losses and cash burn.

BridgeBio Pharma (BBIO) presented at the Morgan Stanley conference, highlighting growth driven by Attruby, which generated $222M in U.S. revenue last quarter. The company reported $100M quarterly losses, expects break-even by 2027-2028, and raised $1B in equity, boosting cash to $1.7B. Management anticipates three near-term drug launches and long-term value from its pipeline.

BridgeBio Pharma, Inc. has 133,900 preferred stocks under a lock-up agreement ending on 13-SEP-2026. The selling stockholder agreed not to sell or hedge common stock for 30 days post-prospectus, except with consent. The company focuses on genetic disease treatments, with several programs in development.

Analysts reiterated Buy ratings for BridgeBio Pharma (BBIO) with a $120 price target, EyePoint Pharmaceuticals (EYPT) with a $17 target, and Abbott Laboratories (ABT) with a $125 target. BBIO and ABT have Strong Buy consensus, while EYPT has Moderate Buy.

BridgeBio Pharma (BBIO) reported Phase 3 PROPEL 3 trial results showing oral Infigratinib benefits in children with achondroplasia beyond growth, including sleep apnea and ear infections. The therapy reduced sleep apnea progression and ear infection rates compared to placebo, with improvements in body composition. Longer-term data showed sustained growth and proportionality improvements. BBIO filed a New Drug Application with the FDA and anticipates a U.S. launch in mid-2027. The stock closed at

BridgeBio (BBIO) reported Phase 3 study data showing some acoramidis-treated patients had cardiac improvements. 54% showed left ventricular function improvement at 30 months, per completer analysis. Separate analysis found 34% improvement. Treatment also reduced days lost to death or hospitalization. BridgeBio plans a Phase 3b/4 study to further evaluate acoramidis.

Nine drugmakers, including Astellas and Sun Pharma, joined Trump's drug-pricing initiative. Novartis paused cell therapy trials but saw success in MS drug trials. CDC excluded two measles deaths from the national tally. Pfizer's Paxlovid showed no benefit in long COVID trial.

President Trump announced agreements with nine pharmaceutical companies to lower U.S. drug prices to match the lowest prices paid by other developed nations. The deals cover 89% of the branded drug market and include investments in U.S. manufacturing and donations to the Strategic Active Pharmaceutical Ingredients Reserve. Companies involved include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements aim to save American

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

President Trump expanded his Most-Favored-Nation drug pricing initiative to 26 companies, covering 89% of the branded drug market. New participants include Alcon, Astellas Pharma, and Teva, among others, agreeing to tie Medicaid drug prices to those in other developed countries. The deals also involve $19.6 billion in U.S. manufacturing investments. According to HHS Secretary Robert F. Kennedy Jr., the agreements cover nine out of 10 drugs used by Americans.